Portola Pharmaceuticals, Inc.
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics in the areas of thrombosis and other hematologic conditions. It is a subsidiary of Alexion, AstraZeneca Rare Disease, which acquired Portola in 2020.
Therapeutic areas
ThrombosisHematology
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Portola Pharmaceuticals, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.